The U.S. transdermal drug delivery system market size was valued at USD 14.7 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 9.5% from 2019 to 2026. Increasing demand for painless drug delivery, coupled with rising demand for self-administration of drugs, is anticipated to fuel market growth. The market is also propelled by ongoing technological advancements in the field. Smart patches, for instance, allow auto-injection of medication and help in monitoring various body parameters. They also enable the transmission of patient-generated data, thereby improving timing and accuracy of drug administration.
According to data by the Center for Disease Control and Prevention (CDC), nearly 6 in every 10 American adults have a chronic disease, while 4 in 10 American adults have more than one chronic disease. The high prevalence of chronic disorders is anticipated to fuel the market for transdermal drug delivery systems. Cardiovascular disorders, diabetes, and Alzheimer’s are some of the main chronic conditions affecting U.S. citizens. These conditions require around the clock monitoring and frequent dose administration, thus facilitating market growth.
Introduction of microneedles patches is anticipated to drive the market. This can be attributed to various benefits of microneedle patches such as rapid onset of action, improved efficacy and skin permeability, self-administration, and improved patient compliance. Furthermore, microneedle patches are able to bypass the stratum corneum and ensure 100% delivery of the loaded drug into the upper dermis or epidermis layer without any pain. These advantages will ensure product demand.
On the down side, high costs associated with development of novel drug-patch combination is anticipated to limit investments in transdermal drug delivery systems. For instance, according to the CEO of Noven Pharmaceuticals, the cost of developing a novel molecule-patch combination is nearly USD 2 billion while the cost of developing a generic transdermal patch is less than 5% of the cost of a novel patch.
Based on technology, the U.S. transdermal drug delivery system market is segmented into active and passive. Passive transdermal drug delivery systems, sub-segmented into matrix and reservoir, dominated the market in 2018 accounting for more than 50.0% of the market revenue. This can be attributed to the relatively low development costs of this patch system. Furthermore, recent developments in passive transdermal drug delivery are anticipated to fuel market growth. For instance, the Delivery-Optimized Thermodynamic (DOT) patch system enables higher drug loading in small patch size, thus facilitating segment growth. On the other hand, the active transdermal drug delivery system is anticipated to witness lucrative growth over the forecast period. Introduction of advanced drug delivery technologies such as Iontophoresis, electroporation,sonophoresis, and microneedle arrays is anticipated to fuel segment growth.
Based on application, the market is segmented into hormone, central nervous system, neurodegenerative, addictive therapies, urology, cardiology, and pain management. Pain management segment held the largest share in the market for transdermal drug delivery systems in 2018. This can be attributed to high availability of several opioids and nonopioids analgesic patches in the market. Global prevalence of pain and chronic pain is a major factor driving this segment. According to the International Association for the Study of Pain (IASP), an estimated 1 in 5 adults suffer from pain each year, globally, and 1 in 10 adults are diagnosed with chronic pain. The Centers for Disease Control and Prevention (CDC) states that in 2016, approximately 20.4% of adults in U.S. suffered from chronic pain.
The hormone segment is anticipated to grow at a rapid pace over the forecast period. High prevalence of hormonal imbalance, especially among women, is anticipated to boost demand for transdermal drug delivery systems. For instance, a survey of 2,000 American women aged 30 to 60 years conducted by OnePoll found that nearly 47.0% have experienced some symptoms of hormonal imbalance.
Mergers and acquisitions form one of the key sustainable strategies undertaken by market players. For instance, Actavis acquired Allergan in March 2015 to strengthen its market position and expand its product portfolio. This rebranding enabled Actavis to leverage the brand awareness associated with Allergan. Some of the prominent players in the U.S. transdermal drug delivery system market include:
Amneal Pharmaceuticals LLC
Novartis AG
3M
AdhexPharma
Johnson & Johnson
Mylan Pharmaceuticals Inc.
Noven Pharmaceuticals Inc.
LTS Lohmann Therapie-Systeme AG
Teva Pharmaceutical Inc.
TherapeuticsMD
Corium International
Taho Pharmaceuticals Ltd.
Report Attribute |
Details |
Market size value in 2020 |
USD 17.6 billion |
Revenue forecast in 2026 |
USD 30.5 billion |
Growth Rate |
CAGR of 9.5% from 2019 to 2026 |
Base year for estimation |
2018 |
Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Quantitative units |
Revenue in USD million and CAGR from 2019 to 2026 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Technology, application |
Country scope |
U.S. |
Key companies profiled |
Amneal Pharmaceuticals LLC; Novartis AG;3M; AdhexPharma; Johnson & Johnson; Mylan Pharmaceuticals, Inc.; Noven Pharmaceuticals, Inc.; LTS Lohmann Therapie-Systeme AG; Teva Pharmaceutical Inc.; TherapeuticsMD; Corium International; Taho Pharmaceuticals Ltd. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at a country level and provides an analysis on the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the U.S. transdermal drug delivery system market report on the basis of technology and application:
Technology Outlook (Revenue, USD Million, 2015 - 2026)
Active
Passive
Matrix
Reservoir
Application Outlook (Revenue, USD Million, 2015 - 2026)
CNS
Nausea & Vomiting
ADHD
Pain management
Hormone
Men
Women
Addiction therapies
Cardiology
Hypertension
Angina
Urology
Neurodegenerative
Parkinson’s Disease
Alzheimer’s Disease
b. The U.S. transdermal drug delivery system market size was estimated at USD 16.1 billion in 2019 and is expected to reach USD 17.6 billion in 2020.
b. The U.S. transdermal drug delivery system market is expected to grow at a compound annual growth rate of 9.5% from 2019 to 2026 to reach USD 30.5 billion by 2026.
b. Passive segment dominated the U.S. transdermal drug delivery system market with a share of 55.7% in 2019. This is attributable to easy development process of these patches
b. Some key players operating in the U.S. transdermal drug delivery system market include Corium International; TherapeuticsMD; Johnson & Johnson; Boehringer Ingelheim GmbH; Novartis AG; Mylan Pharmaceuticals, Inc.; The Tapemark Company; 3M; and AdhexPharma.
b. Key factors that are driving the market growth include increasing demand for painless drug delivery and rising demand for self-administration of drugs
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.